Pembrolizumab-induced pneumonitis

ERJ Open Research

Volumn 3, Issue 2, 2017, Pages

  Leroy, Vincent ^a   Templier, Carole ^a   Faivre, Jean Baptiste ^a   Scherpereel, Arnaud ^a,b   Fournier, Clement ^a   Mortier, Laurent ^a,b   Wemeau Stervinou, Lidwine ^a  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b UNIV LILLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

LACTATE DEHYDROGENASE; PEMBROLIZUMAB; PREDNISOLONE;

ADULT; AGED; ARTERIAL OXYGEN SATURATION; BRONCHOALVEOLAR LAVAGE FLUID; CASE REPORT; CELL CYCLE CHECKPOINT; CLINICAL TRIAL (TOPIC); COMPUTER ASSISTED TOMOGRAPHY; COUGHING; DRUG DOSE REDUCTION; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; DYSPNEA; HUMAN; INTERSTITIAL LUNG DISEASE; LETTER; LUNG CAPACITY; LUNG METASTASIS; LUNG NODULE; MALE; METASTATIC MELANOMA; MIDDLE AGED; PLEURA EFFUSION; PLEURA METASTASIS; PNEUMONIA; PULSE OXIMETRY; THORACOCENTESIS; VERY ELDERLY;

EID: 85081978436     PISSN: None     EISSN: 23120541     Source Type: Journal    
DOI: 10.1183/23120541.00081-2016     Document Type: Letter

References (17)

1. Tumeh PC, Harview CL, Yearley JH, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014; 515: 568-571.
2. Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 2015; 372: 2018-2028.
3. Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 2015; 372: 2521-2532.
4. Ribas A, Puzanov I, Dummer R, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol 2015; 16: 908-918.
5. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 2015; 373: 1627-1639.
6. Weber JS, D’Angelo SP, Minor D, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 2015; 16: 375-384.
7. Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015; 372: 320-330.
8. Rizvi NA, Mazières J, Planchard D, et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol 2015; 16: 257-265.
9. Gettinger SN, Horn L, Gandhi L, et al. Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 2015; 33: 2004-2012.
10. Herbst RS, Baas P, Kim D-W, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 2015; 387: 1540-1550.
11. Sano T, Uhara H, Mikoshiba Y, et al. Nivolumab-induced organizing pneumonia in a melanoma patient. Jpn J Clin Oncol 2016; 46: 270-272.
12. Nishino M, Sholl LM, Hodi FS, et al. Anti-PD-1-related pneumonitis during cancer immunotherapy. N Engl J Med 2015; 373: 288-290.
13. Fragkou P, Souli M, Theochari M, et al. A case of organizing pneumonia (OP) associated with pembrolizumab. Drug Target Insights 2016; 10: 9-12.
14. Cousin S, Toulmonde M, Kind M, et al. Pulmonary sarcoidosis induced by the anti-PD1 monoclonal antibody pembrolizumab. Ann Oncol 2016; 27: 1178-1179.
15. Paydas S. Pulmonary sarcoidosis induced by the anti-PD-1 monoclonal antibody pembrolizumab or post-immunotherapy granulomatous reaction: which is more appropriate terminology? Ann Oncol 2016; 27: 1650-1651.
16. Sul J, Blumenthal GM, Jiang X, et al. FDA approval summary: pembrolizumab for the treatment of patients with metastatic non-small cell lung cancer whose tumors express programmed death-ligand 1. Oncologist 2016; 21: 643-650.
17. Spain L, Diem S, Larkin J. Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev 2016; 44: 51-60.